Engineered antigen-specific T regulatory cells suppress autoreactivity to the anti–glomerular basement membrane disease antigen

Peter J. Eggenhuizen, Boaz H. Ng, Cecilia Lo, Janet Chang, Sarah L. Snelgrove, Rachel M.Y. Cheong, Chanjuan Shen, Steven Lim, Yong Zhong, Poh Yi Gan, Joshua D. Ooi

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Anti–glomerular basement membrane (anti-GBM) disease is accompanied by insufficient antigen-specific regulatory T cells (Tregs) and clonally expanded antigen-specific conventional T cells. In particular, this applied to the immunodominant T cell autoepitope of type IV collagen, α3(IV)NC1135–145, presented by human leukocyte antigen–DRB1∗1501. Here, we investigated whether Tregs engineered to express GBM–T cell receptors (TCR) specific for α3(IV)NC1135–145 better suppress autoimmunity. The GBM-TCR Treg cell product exhibited a phenotypically stable Treg phenotype, produced α3(IV)NC1135–145–specific functional responses, and were superior suppressors of autoreactive conventional T cells and bystander conventional T cells compared to polyclonal Tregs or irrelevant TCR-transduced Tregs. We also found that GBM-TCR Tregs modulate other immune cells like dendritic cells and B cells to a more tolerogenic phenotype. Importantly, our findings support the development of GBM-TCR Tregs as a promising cell-based therapy for anti-GBM disease.

Original languageEnglish
Pages (from-to)751-756
Number of pages6
JournalKidney International
Volume107
Issue number4
DOIs
Publication statusPublished - Apr 2025

Keywords

  • anti–glomerular basement membrane (GBM) disease
  • autoimmune disease
  • cell therapy
  • glomerulonephritis (GN)
  • regulatory T cell (Treg)
  • T-cell receptor (TCR)

Cite this